QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Acitretin is used to treat severe, resistant forms of psoriasis (psoriasis) or other severe cornification disorders of the skin. It is taken orally as a capsule. Acitretin is a second generation retinoid (a derivative of retinoic acid). It binds to receptors in the cell nucleus that regulate gene reading and thus hinder the differentiation (development) of keratinocytes (horn cells). The excessive growth of the epithelial layer (upper skin layer) is normalized and the keratinization of the skin cells slowed down. The effect occurs after about two to four weeks. Very frequent undesirable effects include dryness of the eyes, inflammation of the cornea (keratitis), water retention in the body, dry mouth, increased thirst and desquamation reactions all over the body. At high doses, especially in high-risk patients (diabetics, smokers, overweight people), cholesterol and triglycerides in the blood can rise. Acitretin is teratogenic, so women must be guaranteed safe contraception.
The warnings are checked for the combination of several active substances. For the individual substances, please consult the relevant specialist information.
Since only acitretin was entered without any further substances, no pharmacokinetic interactions can be detected.
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
Acitretin has a mean oral bioavailability [ F ] of 60%, which is why the maximum plasma levels [Cmax] tend to change with an interaction. The terminal half-life [ t12 ] is rather long at 49 hours and constant plasma levels [ Css ] are only reached after more than 196 hours. The protein binding [ Pb ] is very strong at 99.9%. The metabolism does not take place via the common cytochromes.
|Serotonergic Effects a||0||Ø|
Rating: According to our knowledge, acitretin does not increase serotonergic activity.
|Kiesel & Durán b||0||Ø|
Rating: According to our findings, acitretin does not increase anticholinergic activity.
QT time prolongation
We do not know of any QT-prolonging potential for acitretin.
General adverse effects
|Side effects||∑ frequency||aci|
|Dry skin||37.5 %||37.5|
Depression (5.5%): acitretin
Hearing loss: acitretin
Myocardial infarction: acitretin
Pseudotumor cerebri: acitretin
Based on your
No literature information available.